Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses

International Journal of Cancer

Volumn 79, Issue 6, 1998, Pages 640-644

  Weller, Michael ^a   Rieger, Johannes ^a   Grimmel, Cornelia ^a   Van Meir, Erwin G ^b,c,d   De Tribolet, Nicolas ^b,d   Krajewski, Stanislaw ^d   Reed, John C ^d   Von Deimling, Andreas ^e   Dichgans, Johannes ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BURNHAM INSTITUTE   (United States)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA LAPACHONE; CAMPTOTHECIN; CARMUSTINE; CYTARABINE; DOXORUBICIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; TENIPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CYTOTOXICITY TEST; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, P53; GENES, RETINOBLASTOMA; GLIOMA; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0031767393     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981218)79:6<640::AID-IJC15>3.0.CO;2-Z     Document Type: Article

References (22)

1. ALBERTONI, M., DAUB, D.M., ARDEN, K.C., VIARS, C.S., POWELL, C. and VAN MEIR, E.G., Genetic instability leads to loss of both p53 alleles in a human glioblastoma. Oncogene, 16, 321-326 (1998).
2. ARAP, W., KNUDSEN, E., SEWELL, D.A., SIDRANSKY, D., WANG, J.Y.J., HUANG, H.J.S. and CAVENEE, W.K., Functional analysis of wild-type and malignant glioma derived CDKN2Aβ alleles: evidence for an RB-independent growth suppressive pathway. Oncogene, 15, 2013-2020 (1997).
3. ARAP, W., NISHIKAWA, R., FURNARI, F., CAVENEE, W.K. and HUANG, H.J.S., Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res., 55, 1351-1354 (1995).
4. CHINTALA, S.K., FUEYO, J., GOMEZ-MANZANO, C., VENKAIAH, B., BJERKVIG, R., YUNG, W.K.A., SAWAYA, R., KYRITSIS, A.P. and RAO, J.S., Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene, 15, 2049-2057 (1997).
5. CHOZICK, B.S., PEZZULLO, J.C., EPSTELN, M.H. and FINCH, P.W., Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery, 35, 831-838 (1994).
6. ELLISON, D.W., STEART, P.V., BARTEMAN, A.C., PICKERING, R.M., PALMER, J.D. and WELLER, R.O., Prognostic indicators in a range of astrocytic tumors: an immunohistochemical study with Ki-67 and p53 antibodies. J. Neurol. Neurosurg. Psychiatry, 59, 413-419 (1995).
7. GRAEBER, T.G., OSMANIAN, C., JACKS, T., HOUSMAN, D.E., KOCH, C.J., LOWE, S.W. and GIACCLA, A.J., Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature (Lond.), 379, 88-91 (1996).
8. HAYASHI, Y., UEKI, K., WAHA, A., WIESTLER, O.D., Louis, D.N. and VON DEIMLING, A., Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol., 7, 871-875 (1997).
9. KRAJEWSKI, S., KRAJEWSKA, M., EHRMANN, J., SIKORSKA, M., BOLESLAW, L., CHATTEN, J. and REED, J.C., Immunohistochemical analysis of Bcl-2, Bcl-x, Mcl-1 and Bax in tumors of central and peripheral nervous system origin. Amer. J. Pathol., 150, 805-814 (1997).
10. KYRITSIS, A.P., BONDY, M.L., HESS, K.R., CUNNINGHAM, J.E., ZHU, D., AMOS, C.J., YUNG, W.K.A., LEVIN, V.A. and BRUNER, J.M., Prognostic significance of p53 immunoreactivity in patients with glioma. Clin. Cancer Res., 1, 1617-1622 (1995).
11. LIANG, B.C., Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J. Neuro-Oncol., 29, 149-155 (1996).
12. MIYASHITA, T. and REED, J.C., Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell, 80, 293-299 (1995).
13. NEWCOMB, E.W., BHALLA, S.K., PARRISH, C.L., HAYES, R.L., COHEN, H. and MILLER, D.C., Bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta neuropathol., 94, 369-375 (1997).
14. POLLACK, I.F., HAMILTON, R.L., FINKELSTEIN, S.D., CAMPBELL, J.W., MARTINEZ, A.J., SHERWIN, R.N., BOZIK, M.E. and COLLIN, S.M., The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res., 57, 304-309 (1997).
15. RIEGER, L., WELLER, M., BORNEMANN, A., SCHABET, M., DICHGANS, J. and MEYERMANN, R., BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J. neurol. Sci., 155, 68-75 (1998).
16. ROLLBROCKER, B., WAHA, A., LOUIS, D.N., WIESTLER, O.D., and VON DEIMLING, A., Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. Acta neuropathol., 92, 70-74 (1996).
17. TREPEL, M., GROSCURTH, P., MALIPIERO, U., GULBINS, E., DICHGANS, J. and WELLER, M., Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. J. Neuro-Oncol., 39, 19-32 (1998).
18. VAN MEIR, E.G., KIKUCHI, T., TADA, M., LI, H., DISERENS, A.C., WOJCIK, B.E., HUANG, J.S., FRIEDMANN, T., DE TRIBOLET, N. and CAVENEE, W.K., Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res., 54, 649-652 (1994).
19. WELLER, M., Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res., 292, 435-445 (1998).
20. WELLER, M., MALIPIERO, U.V., AGUZZI, A., REED, J.C. and FONTANA, A., Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. clin. Invest., 95, 2633-2643 (1995).
21. WELLER, M., SCHMIDT, C., ROTH, W. and DICHGANS, J., Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology, 48, 1704-1709 (1991a).
22. WELLER, M., WINTER, S., SCHMIDT, C., ESSER, P., FONTANA, A., DICHGANS, J. and GROSCURTH, P., Topoisomerase I inhibitors for human malignant glioma. Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and β-lapachone. Int. J. Cancer, 73, 707-714 (1997b).